SAB Biotherapeutics
SABS
SABS
25 hedge funds and large institutions have $8.48M invested in SAB Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Holders
25
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$293K | |
| 2 | +$51.8K | |
| 3 | +$32.2K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$27.8K |
| 5 |
BlackRock
New York
|
+$22.7K |
Top Sellers
| 1 | -$356K | |
| 2 | -$2.26K | |
| 3 | -$832 | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$184 |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$19 |